Literature DB >> 32762790

Association Between Visual Memory and In Vivo Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease.

Yamile Bocanegra1, Joshua T Fox-Fuller2,3, Ana Baena1, Edmarie Guzmán-Vélez2, Clara Vila-Castelar2, Jairo Martínez2, Heirangi Torrico-Teave2, Francisco Lopera1, Yakeel T Quiroz1,2.   

Abstract

OBJECTIVE: Visual memory (ViM) declines early in Alzheimer's disease (AD). However, it is unclear whether ViM impairment is evident in the preclinical stage and relates to markers of AD pathology. We examined the relationship between ViM performance and in vivo markers of brain pathology in individuals with autosomal dominant AD (ADAD).
METHODS: Forty-five cognitively unimpaired individuals from a Colombian kindred with the Presenilin 1 (PSEN1) E280A ADAD mutation (19 carriers and 26 noncarriers) completed the Rey-Osterrieth Complex Figure immediate recall test, a measure of ViM. Cortical amyloid burden and regional tau deposition in the entorhinal cortex (EC) and inferior temporal cortex (IT) were measured using 11C-Pittsburgh compound B positron emission tomography (PET) and 11F-flortaucipir PET, respectively.
RESULTS: Cognitively unimpaired carriers and noncarriers did not differ on ViM performance. Compared to noncarriers, carriers had higher levels of cortical amyloid and regional tau in both the EC and IT. In cognitively unimpaired carriers, greater cortical amyloid burden, higher levels of regional tau, and greater age were associated with worse ViM performance. Only a moderate correlation between regional tau and ViM performance remained after adjusting for verbal memory scores. None of these correlations were observed in noncarriers.
CONCLUSIONS: Results suggest that AD pathology and greater age are associated with worse ViM performance in ADAD before the onset of clinical symptoms. Further investigation with larger samples and longitudinal follow-up is needed to examine the utility of ViM measures for identifying individuals at high risk of developing dementia later in life.

Entities:  

Keywords:  ADAD; Alzheimer’s disease; Amyloid; Neuropsychological testing; Preclinical; Rey–Osterrieth Complex Figure; Tau; Visual memory

Mesh:

Substances:

Year:  2020        PMID: 32762790      PMCID: PMC8101259          DOI: 10.1017/S1355617720000673

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  43 in total

1.  Retention rates on RBANS memory subtests in elderly adults.

Authors:  Mike R Schoenberg; Kevin Duff; Leigh J Beglinger; David J Moser; John D Bayless; James Mold; James G Scott; Russell L Adams
Journal:  J Geriatr Psychiatry Neurol       Date:  2008-03       Impact factor: 2.680

2.  Visual recognition memory: a double anatomo-functional dissociation.

Authors:  Emmanuel J Barbeau; Jérémie Pariente; Olivier Felician; Michèle Puel
Journal:  Hippocampus       Date:  2010-11-03       Impact factor: 3.899

3.  Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.

Authors:  Reisa A Sperling; Keith A Johnson; P Murali Doraiswamy; Eric M Reiman; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Alan Carpenter; Mat D Davis; Ming Lu; Matthew Flitter; Abhinay D Joshi; Christopher M Clark; Michael Grundman; Mark A Mintun; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  Neurobiol Aging       Date:  2012-08-09       Impact factor: 4.673

4.  Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults.

Authors:  Simone Hollands; Yen Ying Lim; Rachel Buckley; Robert H Pietrzak; Peter J Snyder; David Ames; Kathryn A Ellis; Karra Harrington; Nicola Lautenschlager; Ralph N Martins; Colin L Masters; Victor L Villemagne; Christopher C Rowe; Paul Maruff
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Napatkamon Ayutyanont; Liliana Lopez; Sonia Moreno; Claudia Muñoz; Victoria Tirado; Natalia Acosta-Baena; Anne M Fagan; Margarita Giraldo; Gloria Garcia; Matthew J Huentelman; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

6.  Real-world navigation in amnestic mild cognitive impairment: The relation to visuospatial memory and volume of hippocampal subregions.

Authors:  Jessica Peter; Richard Sandkamp; Lora Minkova; Lena V Schumacher; Christoph P Kaller; Ahmed Abdulkadir; Stefan Klöppel
Journal:  Neuropsychologia       Date:  2017-12-10       Impact factor: 3.139

7.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.

Authors:  Natalia Acosta-Baena; Diego Sepulveda-Falla; Carlos Mario Lopera-Gómez; Mario César Jaramillo-Elorza; Sonia Moreno; Daniel Camilo Aguirre-Acevedo; Amanda Saldarriaga; Francisco Lopera
Journal:  Lancet Neurol       Date:  2011-02-04       Impact factor: 44.182

8.  Entorhinal cortex structure and functional MRI response during an associative verbal memory task.

Authors:  Meredith N Braskie; Gary W Small; Susan Y Bookheimer
Journal:  Hum Brain Mapp       Date:  2009-12       Impact factor: 5.038

9.  Amyloid burden and neural function in people at risk for Alzheimer's Disease.

Authors:  Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Jennifer M Oh; Sandra Harding; Guofan Xu; Ansel T Hillmer; Dustin W Wooten; Dhanabalan Murali; Todd E Barnhart; Lance T Hall; Annie M Racine; William E Klunk; Chester A Mathis; Barbara B Bendlin; Catherine L Gallagher; Cynthia M Carlsson; Howard A Rowley; Bruce P Hermann; N Maritza Dowling; Sanjay Asthana; Mark A Sager
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

10.  The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.

Authors:  Pierre N Tariot; Francisco Lopera; Jessica B Langbaum; Ronald G Thomas; Suzanne Hendrix; Lon S Schneider; Silvia Rios-Romenets; Margarita Giraldo; Natalia Acosta; Carlos Tobon; Claudia Ramos; Alejandro Espinosa; William Cho; Michael Ward; David Clayton; Michael Friesenhahn; Howard Mackey; Lee Honigberg; Sandra Sanabria Bohorquez; Kewei Chen; Trisha Walsh; Carolyn Langlois; Eric M Reiman
Journal:  Alzheimers Dement (N Y)       Date:  2018-03-08
View more
  2 in total

1.  Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer's disease: A cross-sectional study.

Authors:  Joshua T Fox-Fuller; Heirangi Torrico-Teave; Federico d'Oleire Uquillas; Kewei Chen; Yi Su; Yinghua Chen; Michael Brickhouse; Justin S Sanchez; Cinthya Aguero; Heidi I L Jacobs; Olivia Hampton; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Daniel C Aguirre-Acevedo; Ana Baena; Arabiye Artola; Jairo Martinez; Celina F Pluim; Sergio Alvarez; Martin Ochoa-Escudero; Eric M Reiman; Reisa A Sperling; Francisco Lopera; Keith A Johnson; Bradford C Dickerson; Yakeel T Quiroz
Journal:  Alzheimers Dement (Amst)       Date:  2021-09-14

2.  Neuropsychological profile in the preclinical stages of dementia: principal component analysis approach.

Authors:  Claudia Rivera-Fernández; Nilton Custodio; Marcio Soto-Añari
Journal:  Dement Neuropsychol       Date:  2021 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.